Yu, Johnny X.
Suh, Jung Min https://orcid.org/0000-0002-1210-8460
Popova, Katerina D.
Garcia, Kristle https://orcid.org/0000-0002-9868-8397
Joshi, Tanvi https://orcid.org/0009-0001-5051-7927
Culbertson, Bruce
Spinelli, Jessica B. https://orcid.org/0000-0003-3657-4578
Subramanyam, Vishvak
Lou, Kevin https://orcid.org/0000-0003-4939-4381
Charbonneau, Trey
Shokat, Kevan M. https://orcid.org/0000-0001-8590-7741
Weissman, Jonathan https://orcid.org/0000-0003-2445-670X
Goodarzi, Hani https://orcid.org/0000-0002-9648-8949
Funding for this research was provided by:
UC | UC San Francisco | School of Medicine, University of California, San Francisco (Program for Breakthrough Biomedical Research)
UC | UC San Francisco | School of Medicine, University of California, San Francisco (RRP IMIA)
U.S. Department of Health & Human Services | National Institutes of Health (1S10OD028511-01)
U.S. Department of Health & Human Services | National Institutes of Health (F30CA239476)
U.S. Department of Health & Human Services | National Institutes of Health (5R01CA244550)
National Science Foundation (GRFP)
National Science Foundation (GRFP)
Howard Hughes Medical Institute
Samuel Waxman Cancer Research Foundation
Article History
Received: 16 January 2024
Accepted: 22 January 2026
First Online: 24 February 2026
Competing interests
: J.X.Y., K.M.S. and H.G. are cofounders and shareholders of Tahoe Therapeutics. The other authors declare no competing interests.